Whenever this Kat writes about AI, responses have started to move away from talk about hallucination, confidentiality or quality. The new concern is one of economics, i.e. will the whole AI thing just become too expensive and are we putting ourselves at risk by outsourcing to AI. It is argued that AI tools are currently
Latest Post
More Posts
New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)
AI in the patent industry: The risks of AI shadow use
Be careful what you wish for: Method of treatment claim for an antibody genus found to satisfy both written description and enablement requirement (Teva v Eli Lilly)
Navigating the complex LNP IP landscape
Patenting the use of medical devices (T 0941/24)
Human definitions versus biological reality (T 630/24)
AI in the patent industry: Don’t believe the hype. Believe the data.
Sequence identities and functional definitions – where is the limit? (T 0137/24)
Patenting stem cell therapies in the US: The role and risks of product-by-process claims (Restem v Jadi cell)
Subscribe: Subscribe via RSS